L1 Capital Pty Ltd purchased $3.0M of AVR (indirect holdings)
L1 Capital Pty Ltd purchased 397,226 indirectly-held shares of Anteris Technologies Global Corp. (AVR) at an average of $7.62 ($7.60–$7.72, $3.03M total) across 2 trades over 2026-09-30 to 2026-10-01.
How this was made
The 30-second read
Why it matters
The $3M purchase increases the insider's stake, indicating confidence and possibly prompting other investors to buy.
Market read
Insider buying of a micro‑cap biotech can move the stock modestly; traders may watch for price reaction.
What to watch
Potential upcoming clinical data or regulatory events not disclosed could amplify the effect.
Background
Form 4 filings disclose insider transactions; L1 Capital Pty Ltd is a 10% owner of Anteris Technologies.
Ticker impact
SEC Form 4 shows L1 Capital Pty Ltd bought 397,226 shares of Anteris Technologies (AVR) for $3.03M, increasing its stake to over 5.2M shares.
potential upward pressure as the market prices in the insider buying signal
Form 4 filings are primary disclosures; a $3M purchase by a 10% owner is material for a micro‑cap biotech and can trigger buying interest.
Market effects
May signal confidence in Anteris' pipeline, modestly supportive for the biotech sector.
Limited to US biotech investors; no broader regional effect.
Low global impact; primarily relevant to AVR shareholders.
Counterpoint
The purchase could be a strategic stake without immediate operational impact; price may remain flat.
Key entities
- companyAnteris Technologies Global Corp.
Biotech firm listed on Nasdaq under ticker AVR.
- investorL1 Capital Pty Ltd
10% owner of Anteris Technologies, executed the purchase.
